Is segmentectomy suitable for solid-type lung cancer?  by Sawabata, Noriyoshi
Letters to the Editorhow mortality figures cannot be
entirely relied on to dictate health
policy.2
One, therefore, has to objectively
assess its merits and drawbacks
without recourse to pressure from po-
litical drives for greater transparency.
One potential advantage is that pub-
lic disclosure removes the fortifica-
tions inherent in local clinical
governance where staff may be con-
cerned about stigmatism associated
with whistle blowing. Another advan-
tage is that it allows for a more accu-
rate informed consent process for
patients.
There is a perceived third advan-
tage in that it would drive up surgical
performance on the part of the indi-
vidual surgeon. However, this may
actually be counterproductive. Car-
diac surgeons are by nature a highly
successful and competitive niche,
and this drive for excellence alone
has brought down mortality rates
over the past 3 decades. By forcing
surgeons to disclose their figures,
there is the potential for risk-
aversion on their part in an attempt
to artificially improve their figures
to compete for cases and their own
survival.3
However, possibly the greatest crit-
icism of this public disclosure is that
by publishing surgeons’ mortality
rates in isolation, it implies that they
are singularly responsible when things
go wrong. The management of the
surgical patient is, by all intents and
purposes, a process. The cardiac sur-
geon has the privilege of being closely
involved in the whole process but he
or she is certainly not omnipotent.
The safe and rapid recovery of the sur-
gical patient is as much dependent on
the allied health care professionals
involved with the patient as it is on
the surgeon. However, this is not
translated in the mortality figures.
Cardiac surgeons therefore seem
alone, staring into an abyss that is
often staring back at them with intent.
Hence, by stripping away the myth
of cardiac surgeons as gods and728 The Journal of Thoracic and Callowing them to be scrutinized as
leaders in a democratic manner, soci-
ety has ironically increased the burden
on them to perform miracles. We
cannot, however, run away from a
greater drive for accountability in the
medical profession. Despite this, the
early lessons learnt from cardiac sur-
gery in the United Kingdom demon-
strate that this framework must be
fair, interpretable, and, above all,
have a clear beneficial purpose in
improving patient care rather than be-
ing an unnecessary process of self-
flagellation.
Priyadharshanan Ariyaratnam,
BM, BSc (Hons), MRCS
Castle Hill Hospital
Cottingham, United Kingdom
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To the Editor:
I am interested in an article entitled
‘‘Oncologic outcomes of segmentec-
tomy compared with lobectomy for
clinical stage IA lung adenocarci-
noma: Propensity score–matched
analysis in a multicenter study,’’ by
Tsutani and colleagues.1 This study,
I believe, revealed noninferiority (not
suitability) of segmentectomy for
clinical stage IA non–small cell lung
cancer, with end points of overall sur-
vival and relapse-free survival.
Because a lung cancer recurrence
that occurred exclusively in casesardiovascular Surgery c September 201of segmentectomy must be that in
the residual pulmonary lobe, such
cancer relapse must be avoided by
performing lobectomy. Approxi-
mately one third of interlobular
sentinel nodes exist at other seg-
ments than the segment containing
a cancerous lesion.2 A lesion
revealing a pure solid pattern using
computed tomography and a high
maximum standard uptake value
(SUVmax) in a fludeoxyglucose
positron emission tomography scan
has high potential of lymph node
metastasis3 and of causing isolated
tumor cells as a cluster (an indicator
of cancer relapse) in the blood.4 This
is because a pure solid-type and high
SUVmax cancer lesion possibly has
high potential of cancer relapse at
the residual lobe after segmentec-
tomy. Indeed, Tsutani and col-
leagues revealed 2 cases of cancer
recurrence at the residual lobe. As
such, segmentectomy should be
carefully indicated in cases having
a high potential of recurrence.
The authors mentioned in the
current article that the result of
a prospective study treating nonin-
feriority of segmentectomy to
lobectomy in cases of peripheral
small-sized non–small cell lung
cancer (JCOG0802/WJOG4607L)5
may provide an important insight
into the issue regarding segmentec-
tomy for a solid cancer lesion with
a high SUVmax level, because
such a case may have high potential
of cancer relapse at the residual
pulmonary lobe in segmentectomy
cases.
I believe it is necessary to perform a
nested analysis extracted from such
cases with a solid-type lung cancer
in the study provided by Tsutani and
colleagues.
Noriyoshi Sawabata, MD, PhD
Department of General Thoracic
Surgery
Osaka University Graduate School of
Medicine
Osaka, Japan3
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We appreciate the comments and
concerns expressed by Dr Sawabata
regarding our article, titled ‘‘Onco-
logic outcomes of segmentectomy
compared with lobectomy for clinical
stage IA lung adenocarcinoma: Pro-
pensity score–matched analysis in a
multicenter study.’’1 We believe any
recurrence in the residual pulmonary
segments after segmentectomy must
be avoided as much as possible, as Sa-
wabata stated. Actually, we experi-
enced 2 recurrences in the residual
segments after segmentectomy in
this study.1 One patient had 2 cm of
pure solid tumor on high-resolution
computed tomography (HRCT). He
underwent resection of left S4þ5 seg-
ments and local recurrence in the sur-
gical stump occurred 6 months after
the operation. The other patient had
2 cm of mixed ground-glass opacity
(GGO) tumor including the majority
of the solid part on HRCT. He under-
went resection of the right S2 segment
and local recurrence developed 24The Journalmonths after the operation. Fortu-
nately, these patients were treated
with completion lobectomy and are
alive well without disease 31 months
and 72 months after the operations,
respectively.
In our study, the independent prog-
nostic factors for local recurrence-free
survival were solid tumor size on
HRCT and maximum standardized
uptake value (SUVmax) on F-18-fluo-
rodeoxyglucose positron emission
tomography/computed tomography
(FDG-PET/CT).1 Therefore, segmen-
tectomy for a tumor that has a large
solid tumor size or a high SUVmax
should be carefully indicated. When
segmentectomy is performed in such
a risky case, taking wide surgical mar-
gins and intraoperative lymph node
assessment using frozen sections are
mandatory. On the other hand, we pre-
viously proposed the N0 criteria of
solid tumor size<0.8 cm or SUVmax
<1.5 for clinical stage IA lung adeno-
carcinoma.2 Patients meeting the N0
criteria can be good candidates for
sublobar resection with sufficient sur-
gical margin including wedge resec-
tion because of little chance to have
pathologic nodal metastasis, for
which we concentrate our attention
on the surgical margin. We also
demonstrated that solid tumor size
on HRCT and SUVmax on FDG-
PET/CT are independent predictors
of pathologic invasiveness, lymph
node metastasis, and prognostic fac-
tors for clinical stage IA lung adeno-
carcinoma.2,3 Optimal surgical
procedure for clinical stage IA lung
adenocarcinoma can be chosen using
solid tumor size on HRCT and
SUVmax on FDG-PET/CT. More-
over, we reported solid tumors
without GGO generally showed worse
pathologic behaviors than mixed tu-
mors with GGO in clinical stage IA
lung adenocarcinoma.4 However, a
solid tumor with low SUVmax can
be a good candidate for segmentec-
tomy because such a tumor has low
malignant potential and shows good
prognosis.2,4of Thoracic and Cardiovascular SurgeWe failed to carry out a subset anal-
ysis comparing segmentectomy with
lobectomy in patients with solid tumor
on HRCT since in only 13 patients we
had performed segmentectomy for
solid tumors. In general, thoracic sur-
geons have tended to choose segmen-
tectomy for a mixed tumor with GGO
in T1 N0 M0 lung adenocarcinoma.
To answer the question ‘‘Is segmen-
tectomy suitable for solid type lung
cancer?’’ we have to await the result
of large phase III trials, CALGB-
140503 in the United States and
JCOG0802/WJOG4607L in Japan.5
We encourage any participants to enroll
patients in these studies.
Yasuhiro Tsutani, MD, PhD
Yoshihiro Miyata, MD, PhD
Morihito Okada, MD, PhD
Department of Surgical Oncology
Hiroshima University
Hiroshima, Japan
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